TY - JOUR T1 - A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality. AU - Fernández-Cruz,Ana, AU - Ruiz-Antorán,Belén, AU - Muñoz-Gómez,Ana, AU - Sancho-López,Aránzazu, AU - Mills-Sánchez,Patricia, AU - Centeno-Soto,Gustavo Adolfo, AU - Blanco-Alonso,Silvia, AU - Javaloyes-Garachana,Laura, AU - Galán-Gómez,Amy, AU - Valencia-Alijo,Ángela, AU - Gómez-Irusta,Javier, AU - Payares-Herrera,Concepción, AU - Morrás-Torre,Ignacio, AU - Sánchez-Chica,Enrique, AU - Delgado-Téllez-de-Cepeda,Laura, AU - Callejas-Díaz,Alejandro, AU - Ramos-Martínez,Antonio, AU - Múñez-Rubio,Elena, AU - Avendaño-Solá,Cristina, Y1 - 2020/08/20/ PY - 2020/06/08/received PY - 2020/06/19/accepted PY - 2020/6/24/pubmed PY - 2020/9/4/medline PY - 2020/6/24/entrez KW - COVID-19 KW - mortality KW - steroids JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 64 IS - 9 N2 - Evidence to support the use of steroids in coronavirus disease 2019 (COVID-19) pneumonia is lacking. We aim to determine the impact of steroid use for COVID-19 pneumonia on hospital mortality. We performed a single-center retrospective cohort study in a university hospital in Madrid, Spain, during March of 2020. To determine the role of steroids in in-hospital mortality, patients admitted with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and treated with steroids were compared to patients not treated with steroids, and we adjusted with a propensity score for patients on steroid treatment. Survival times were compared using the log rank test. Different steroid regimens were compared and adjusted with a second propensity score. During the study period, 463 out of 848 hospitalized patients with COVID-19 pneumonia fulfilled inclusion criteria. Among them, 396 (46.7%) patients were treated with steroids and 67 patients were not. Global mortality was 15.1%. The median time to steroid treatment from symptom onset was 10 days (interquartile range [IQR], 8 to 13 days). In-hospital mortality was lower in patients treated with steroids than in controls (13.9% [55/396] versus 23.9% [16/67]; hazard ratio [HR], 0.51 [95% confidence interval, 0.27 to 0.96]; P = 0.044). Steroid treatment reduced mortality by 41.8% relative to the mortality with no steroid treatment (relative risk reduction, 0.42 [95% confidence interval, 0.048 to 0.65]). Initial treatment with 1 mg/kg of body weight/day of methylprednisolone versus steroid pulses was not associated with in-hospital mortality (13.5% [42/310] versus 15.1% [13/86]; odds ratio [OR], 0.880 [95% confidence interval, 0.449 to 1.726]; P = 0.710). Our results show that the survival of patients with SARS-CoV-2 pneumonia is higher in patients treated with glucocorticoids than in those not treated. Rates of in-hospital mortality were not different between initial regimens of 1 mg/kg/day of methylprednisolone and glucocorticoid pulses. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/32571831/A_Retrospective_Controlled_Cohort_Study_of_the_Impact_of_Glucocorticoid_Treatment_in_SARS_CoV_2_Infection_Mortality_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=32571831 DB - PRIME DP - Unbound Medicine ER -